P/E ratio for Incyte (INCY)
P/E ratio as of July 2025 (TTM): 209
According to Incyte's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 209.122. At the end of 2024 the company had a P/E ratio of 223.
P/E ratio history for Incyte from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 223 | 847.43% |
| 2023 | 23.5 | -54.91% |
| 2022 | 52.2 | 204.83% |
| 2021 | 17.1 | -127.34% |
| 2020 | -62.6 | -249.06% |
| 2019 | 42.0 | -65.67% |
| 2018 | 122 | -301.43% |
| 2017 | -60.7 | -133.91% |
| 2016 | 179 | -96.7% |
| 2015 | > 1000 | -2325.07% |
| 2014 | -244 | 159.92% |
| 2013 | -93.8 | 103.21% |
| 2012 | -46.1 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 27.5 | -86.86% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | -18.5 | -108.84% | 🇺🇸 USA |
 Eli Lilly LLY | 61.7 | -70.47% | 🇺🇸 USA |
 Pfizer PFE | 17.5 | -91.64% | 🇺🇸 USA |
 Geron GERN | -5.40 | -102.58% | 🇺🇸 USA |
 Ardelyx ARDX | -25.8 | -112.35% | 🇺🇸 USA |
 Novartis NVS | 18.2 | -91.28% | 🇨🇭 Switzerland |
 AVEO Oncology
AVEO | -17.9 | -108.54% | 🇺🇸 USA |
 CTI BioPharma
CTIC | -15.7 | -107.49% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.